Selegiline (oral)
This article does not cite any sources. (August 2006) (Learn how and when to remove this template message) |
- ↑
Amsterdam, J. D. (2003-02). "A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder". Journal of Clinical Psychiatry. 64 (2): 208–214. Check date values in:
|date=
(help) - ↑ http://www.fda.gov/bbs/topics/NEWS/2006/NEW01326.html
- ↑ Katzung, Bertram G. Basic & Clinical Pharmacology. 9th Edition. 2004. page 453. Lange Medical Books - McGraw Hill Publishers.
- ↑ Engberg G, Elebring T, Nissbrandt H (1991). "Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons". J. Pharmacol. Exp. Ther. 259 (2): 841–7. PMID 1658311.
Categories:
- CS1 errors: dates
- Pages with script errors
- Articles lacking sources from August 2006
- Articles with invalid date parameter in template
- All articles lacking sources
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list